Genprex, Inc. 8-K

What Happened
On February 23, 2026, Genprex, Inc. announced that the Japanese Patent Office issued a favorable Appeal Decision to grant a patent for using REQORSA® gene therapy in combination with PD-L1 antibodies, and the European Patent Office issued a Decision to Grant a patent for the combination of REQORSA and PD-1 antibodies. Genprex holds an exclusive license to these patents and said the grants complement its existing portfolio of REQORSA combination patents in the U.S., Korea, and other jurisdictions. The company tied these IP developments to its Acclaim-3 Phase 1/2 clinical trial testing REQORSA plus Genentech’s Tecentriq (atezolizumab) as maintenance therapy in extensive-stage small cell lung cancer (ES-SCLC).

Key Details

• Date: press release and Form 8‑K filed February 23, 2026.
• Trial: Acclaim-3 is a Phase 1/2 study; Phase 2 expansion plans to enroll ~50 patients with the primary endpoint of 18-week progression-free survival (PFS) from start of maintenance therapy.
• Timeline: Genprex expects to complete enrollment of the first 25 Phase 2 patients in H1 2026 and perform an interim analysis in H2 2026 after those patients reach 18 weeks of follow-up.
• Prior IP: Genprex already holds granted U.S. and Korean patents for REQORSA + PD-L1 and multiple granted patents for REQORSA + PD-1 in other countries; Australia patent pending.

Why It Matters
These patent grants strengthen Genprex’s intellectual property coverage for combination use of REQORSA with immune checkpoint inhibitors, which is directly relevant to the Acclaim-3 trial and potential future commercialization. Stronger IP in major markets (Japan, EU) can help protect exclusivity for these therapeutic combinations, but the company’s statements are forward-looking and subject to risks (clinical, regulatory, financial) described in its SEC filings. Investors should note the clinical milestones calendar (first 25 patients enrolled in H1 2026; interim analysis in H2 2026) as key near-term events.